Evaluation of the 6-Month Effect of Sacubitril-Valsartan Compared to ACEI and ARB on LVEF in Heart Failure Patients: A Double-Blind Randomized Clinical Trial.

BACKGROUND AND AIM: Heart failure is a common condition that affects millions of people worldwide. The aim of this study was to evaluate the 6-month effect of sacubitril-valsartan (SV) compared to angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) on left ventricular ejection fraction (LVEF) in heart failure patients.

METHODS

This is a clinical trial involving heart failure patients (n = 225) referred to Farshchian Heart Hospital in Hamadan-Iran from April to September 2023. The patients were randomly assigned to three groups receiving SV (n = 75), ACEI (n = 75), and ARB (n = 75). In all three treatment groups, LVEF was checked and compared by echocardiography before the treatment and 6 months after the treatment.

RESULTS

The mean scores of an increase in EF compared to before treatment in the SV, ACEI, and ARB groups were 1.73 ± 2.78%, 0.69 ± 1.93%, and 0.14 ± 1.42%, respectively (P < .001) groups (29.3 vs. 6.7 and 12.7%, P < .001). In addition, no significant difference was observed between the three groups in terms of mortality. The number of hospitalizations and the duration of hospitalization were lower in the sacubitril-valsartan group than in the ACEI and ARB groups.

CONCLUSION

In this study, SV was shown to be superior to ACEI and ARB in improving LVEF in heart failure patients at 6 months follow-up. These findings highlight the potential benefits of SV in the management of heart failure.